BlossomHill Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BLSM | CLYM | AVBP | FTH | FHTX | CBIO | |
|---|---|---|---|---|---|---|
| Market cap | 393.50M | 535.88M | 665.16M | 516.62M | 124.71M | 513.37M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.1 | -9.3 | -3.6 | -5.4 | -2.0 | -5.3 |
| Price/book | -0.2 | 2.2 | 1.8 | 1.4 | -1.5 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −22.44% | +407.81% | −26.64% | +121.53% | −47.50% | +5.07% |
| Today | −0.24% | −4.31% | +3.61% | +1.73% | −1.41% | +5.82% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BLSM news ›Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $43, Maintains Neutral Rating
Vera Therapeutics has an average rating of buy and mean price target of $81.86, according to analysts polled by FactSet. ... Biotechnology & Medical Research Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $43, Maintains…
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
BlossomHill Therapeutics achieved major de-risking milestones with the C797S lung cancer indication as a strategic beachhead. Learn why BLSM stock is a buy. - BlossomHill Therapeutics achieved major de-risking milestones within 80 days…
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at...
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR⢠Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at... 45% objective response rate and 88%…
The Beauty Health Company (NASDAQ:SKIN) Stock Has Average Price Target of $18.00
Posted by Defense World Staff on Oct 28th, 2026 Get Our Latest Analysis on SKIN Shares of NASDAQ:SKIN opened at $10.12 on Wednesday. Beauty Health has a 52-week low of $9.89 and a 52-week high of $34.80. The firm has a fifty day moving…
BlossomHill Therapeutics Presents First Preclinical Data from New Pan-KRAS Inhibitor Program Built on a Novel Chemical Scaffold During Mini Symposium at AACR 2026
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. BH-501284 demonstrated high potency (median IC50 of 0 ...
Outset Medical, Inc. (NASDAQ:OM) Stock Has Average Target Price of $10.00 According to Brokerages
Posted by Kim Johansen on Oct 27th, 2026 Several research analysts have recently issued reports on OM shares. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss…
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting ... BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor,…
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines ... BlossomHill Therapeutics Announces…
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Stock Has Average Price Target of $35.00 According to Analysts
Posted by Defense World Staff on Oct 24th, 2026 Check Out Our Latest Stock Analysis on BlossomHill Therapeutics Shares of BLSM opened at $14.63 on Wednesday. BlossomHill Therapeutics has a 12 month low of $12.93 and a 12 month high of…
More from 1 other outlet
Wedbush Adjusts Price Target on Tango Therapeutics to $45 From $39, Maintains Outperform Rating
Tango Therapeutics has an average rating of buy and mean price target of $45.18, according to analysts polled by FactSet. Price: 23.16, Change: -4.77, Percent Change: -17.08 ... Biotechnology & Medical Research Wedbush Adjusts Price Target…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com8
- marketbeat.com3
- themarketsdaily.com3
- defenseworld.net2
- marketscreener.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.